Is Regeneron Pharmaceuticals (REGN) overvalued or fairly valued?

MarketChacha shows Regeneron Pharmaceuticals's valuation in context — a forward P/E of about 12.0, a price-to-book of about 2.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals last traded at $653.99 (-3.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Regeneron Pharmaceuticals

REGN · NASDAQ · Healthcare · United States

$653.99-3.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:40 PM

Snapshot

TickerREGN

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees15,343

HeadquartersTarrytown, United States

Market cap$68.6B

P/B2.1

Volume334.76K

Websitewww.regeneron.com

Filings tracked0

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Profile as reported by Yahoo Finance.

Who owns it

Insiders2.0%
Institutions94.4%
Public & other3.5%

1,954 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.8.69%
Vanguard Capital Management LLC6.46%
State Street Corporation4.53%
Dodge & Cox Inc.4.33%
JPMORGAN CHASE & CO4.19%
Invesco Ltd.3.79%
Franklin Resources, Inc.2.64%
Geode Capital Management, LLC2.53%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $4.2B · EPS 13.21

Est. earnings growth +11.6%

Next fiscal year

Rev $17.6B · EPS 47.46

Est. earnings growth +19.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$541.0052-wk range$821.11

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about REGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.